Ledger.Open graph →
SEC Form D · filed November 23, 2020

Summit Therapeutics Inc

Offering
$50.0M
Sold
$50.0M
Exemption
Rule 506(b)
Industry
Biotechnology
Location
CAMBRIDGE, MA
Type
—

Rule 506(b): private placement to accredited investors, no public advertising.

People & firms on this filing (18)

Rainer Erdtmann · Cambridge, MADirectorManmeet Soni · Cambridge, MADirectorRobert Duggan · Palo Alto, CAExecMahkam Zanganeh · Palo Alto, CADirectorUjwala Mahatme · Cambridge, MADirectorMichael P. Donaldson · Cambridge, MAExecHoubiers P. Jos · Cambridge, MAExecDavid J. Powell · Cambridge, MAExecCamilla J. Graham · Cambridge, MAExecRobert Duggan · Palo Alto, CAExecMahkam Zanganeh · Palo Alto, CADirectorRainer Erdtmann · Cambridge, MADirectorManmeet Soni · Cambridge, MADirectorUjwala Mahatme · Cambridge, MADirectorMichael P. Donaldson · Cambridge, MAExecHoubiers P. Jos · Cambridge, MAExecDavid J. Powell · Cambridge, MAExecCamilla J. Graham · Cambridge, MAExec

Public SEC Form D (Reg D) filing. · View issuer on SEC EDGAR ↗